The relation between viremia and clinical outcome in individuals infected with human
immunodeficiency virus-type 1 (HIV-1) has important implications for therapeutic research and …

Background: The rate of disease progression among persons infected with human
immunodeficiency virus type 1 (HIV-1) varies widely, and the relative prognostic value of markers of …

Background The new protease inhibitors are potent inhibitors of the human immunodeficiency
virus (HIV), and in combination with other antiretroviral drugs they may be able to cause …

Background Among persons in North America who are newly infected with the human
immunodeficiency virus (HIV), the prevalence of transmitted resistance to antiretroviral drugs has …

Objective: To investigate the relation between the quantity of human immunodeficiency virus
type 1 (HIV-1) RNA in plasma and the risk for the acquired immunodeficiency syndrome (…

Background The use of either efavirenz or lopinavir–ritonavir plus two nucleoside reverse-transcriptase
inhibitors (NRTIs) is recommended for initial therapy for patients with human …

Background Antiretroviral medications that are used as prophylaxis can prevent acquisition
of human immunodeficiency virus type 1 (HIV-1) infection. However, in clinical trials among …

Residual viremia can be detected in most HIV-1-infected patients on antiretroviral therapy
despite suppression of plasma RNA to <50 copies per ml, but the source and duration of this …

More sensitive assays for human immunodeficiency virus type 1 (HIV-1) RNA are needed to
detect, quantify, and characterize persistent viremia in patients who are receiving …

Background Persistent infection in resting CD4+ T cells prevents eradication of HIV-1. Since
the chromatin remodeling enzyme histone deacetylase 1 (HDAC1) maintains latency of …